UPDATED Feb 18, 2024
Defensive mid-caps and large-caps in descending order of expected ROE in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
GSKGSK | UK£16.76 | 3.1% | 13.7% | UK£68.0b | UK£19.87 | PE13.8x | E8.9% | 3.5% | ||
AZNAstraZeneca | UK£100.94 | 6.2% | -12.5% | UK£156.5b | UK£128.59 | PE33.1x | E16.7% | 2.3% | ||
HIKHikma Pharmaceuticals | UK£19.88 | 1.4% | 12.4% | UK£4.4b | UK£22.20 | PE37.9x | E18.4% | 2.5% |